Total Funding
64
13
Total FundingGrant raised
Growth Score
-5 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
40504
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
- Dhaval Patel: Founder & Director
Elisabeth Kueenburg: Chief Medical Officer
About the Company
Priothera is a clinical-stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic
Stem Cell Transplantation (HSCT) in these patients.
